Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Pulmonary Hypertension Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Pulmonary Hypertension Drugmarket, defines the market attractiveness level of Pulmonary Hypertension Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Pulmonary Hypertension Drug industry, describes the types of Pulmonary Hypertension Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global Pulmonary Hypertension Drug market and the development prospects and opportunities of Pulmonary Hypertension Drug industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Pulmonary Hypertension Drug market in Chapter 13.
By Player:
AstraZeneca plc
Merck & Co, Inc
Pfizer Inc
F Hoffmann-La Roche AG
Abbott Laboratories
Novartis AG
Boehringer Ingelheim GmbH
GlaxoSmithKline plc
Vectura Group plc
Teva Pharmaceutical Industries Ltd
By Type:
Prostacyclin and Prostacyclin Analogs
Endothelin Receptor Antagonists
Phosphodiesterase-5 Inhibitors
Soluble Guanylate Cyclase Stimulators
By End-User:
Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase)
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Pulmonary Hypertension Drug Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Pulmonary Hypertension Drug Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Pulmonary Hypertension Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Pulmonary Hypertension Drug Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Pulmonary Hypertension Drug Market Analysis and Outlook to 2022
-
7.1 Global Pulmonary Hypertension Drug Consumption (2017-2022)
-
7.2 United States Pulmonary Hypertension Drug Consumption (2017-2022)
-
7.3 Europe Pulmonary Hypertension Drug Consumption (2017-2022)
-
7.4 China Pulmonary Hypertension Drug Consumption (2017-2022)
-
7.5 Japan Pulmonary Hypertension Drug Consumption (2017-2022)
-
7.6 India Pulmonary Hypertension Drug Consumption (2017-2022)
-
7.7 South Korea Pulmonary Hypertension Drug Consumption (2017-2022)
8 Region and Country-wise Pulmonary Hypertension Drug Market Analysis and Outlook to 2028
-
8.1 Global Pulmonary Hypertension Drug Consumption Forecast (2022-2028)
-
8.2 United States Pulmonary Hypertension Drug Consumption Forecast (2022-2028)
-
8.3 Europe Pulmonary Hypertension Drug Consumption Forecast (2022-2028)
-
8.4 China Pulmonary Hypertension Drug Consumption Forecast (2022-2028)
-
8.5 Japan Pulmonary Hypertension Drug Consumption Forecast (2022-2028)
-
8.6 India Pulmonary Hypertension Drug Consumption Forecast (2022-2028)
-
8.7 South Korea Pulmonary Hypertension Drug Consumption Forecast (2022-2028)
9 Global Pulmonary Hypertension Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Pulmonary Hypertension Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Prostacyclin and Prostacyclin Analogs Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Endothelin Receptor Antagonists Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Phosphodiesterase-5 Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Soluble Guanylate Cyclase Stimulators Consumption and Growth Rate (2017-2022)
-
9.2 Global Pulmonary Hypertension Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Early-stage Drug Candidates (Phase I & Phase II) Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Late-stage Drug Candidates (Phase III & Registration Phase) Consumption and Growth Rate (2017-2022)
10 Global Pulmonary Hypertension Drug Market Outlook by Types and Applications to 2028
-
10.1 Global Pulmonary Hypertension Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Prostacyclin and Prostacyclin Analogs Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Endothelin Receptor Antagonists Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Phosphodiesterase-5 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Soluble Guanylate Cyclase Stimulators Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Pulmonary Hypertension Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Early-stage Drug Candidates (Phase I & Phase II) Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Late-stage Drug Candidates (Phase III & Registration Phase) Consumption Forecast and Growth Rate (2022-2028)
11 Global Pulmonary Hypertension Drug Import and Export Analysis (Top 5 Countries)
-
11.1 Global Pulmonary Hypertension Drug Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Pulmonary Hypertension Drug Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Pulmonary Hypertension Drug Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Pulmonary Hypertension Drug Market Competitive Analysis
-
14.1 AstraZeneca plc
-
14.1.1 AstraZeneca plc Company Details
-
14.1.2 AstraZeneca plc Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 AstraZeneca plc Pulmonary Hypertension Drug Product and Service
-
14.2 Merck & Co, Inc
-
14.2.1 Merck & Co, Inc Company Details
-
14.2.2 Merck & Co, Inc Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Merck & Co, Inc Pulmonary Hypertension Drug Product and Service
-
14.3 Pfizer Inc
-
14.3.1 Pfizer Inc Company Details
-
14.3.2 Pfizer Inc Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Pfizer Inc Pulmonary Hypertension Drug Product and Service
-
14.4 F Hoffmann-La Roche AG
-
14.4.1 F Hoffmann-La Roche AG Company Details
-
14.4.2 F Hoffmann-La Roche AG Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 F Hoffmann-La Roche AG Pulmonary Hypertension Drug Product and Service
-
14.5 Abbott Laboratories
-
14.5.1 Abbott Laboratories Company Details
-
14.5.2 Abbott Laboratories Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Abbott Laboratories Pulmonary Hypertension Drug Product and Service
-
14.6 Novartis AG
-
14.6.1 Novartis AG Company Details
-
14.6.2 Novartis AG Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Novartis AG Pulmonary Hypertension Drug Product and Service
-
14.7 Boehringer Ingelheim GmbH
-
14.7.1 Boehringer Ingelheim GmbH Company Details
-
14.7.2 Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Product and Service
-
14.8 GlaxoSmithKline plc
-
14.8.1 GlaxoSmithKline plc Company Details
-
14.8.2 GlaxoSmithKline plc Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 GlaxoSmithKline plc Pulmonary Hypertension Drug Product and Service
-
14.9 Vectura Group plc
-
14.9.1 Vectura Group plc Company Details
-
14.9.2 Vectura Group plc Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Vectura Group plc Pulmonary Hypertension Drug Product and Service
-
14.10 Teva Pharmaceutical Industries Ltd
-
14.10.1 Teva Pharmaceutical Industries Ltd Company Details
-
14.10.2 Teva Pharmaceutical Industries Ltd Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Teva Pharmaceutical Industries Ltd Pulmonary Hypertension Drug Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Pulmonary Hypertension Drug
-
Figure Pulmonary Hypertension Drug Picture
-
Table Global Pulmonary Hypertension Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Pulmonary Hypertension Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Pulmonary Hypertension Drug Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Pulmonary Hypertension Drug Consumption by Country (2017-2022)
-
Figure United States Pulmonary Hypertension Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Pulmonary Hypertension Drug Consumption and Growth Rate (2017-2022)
-
Figure China Pulmonary Hypertension Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Pulmonary Hypertension Drug Consumption and Growth Rate (2017-2022)
-
Figure India Pulmonary Hypertension Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Pulmonary Hypertension Drug Consumption and Growth Rate (2017-2022)
-
Figure Global Pulmonary Hypertension Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Pulmonary Hypertension Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Pulmonary Hypertension Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Pulmonary Hypertension Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Pulmonary Hypertension Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Pulmonary Hypertension Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Pulmonary Hypertension Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Prostacyclin and Prostacyclin Analogs Consumption and Growth Rate (2017-2022)
-
Figure Global Endothelin Receptor Antagonists Consumption and Growth Rate (2017-2022)
-
Figure Global Phosphodiesterase-5 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Soluble Guanylate Cyclase Stimulators Consumption and Growth Rate (2017-2022)
-
Figure Global Early-stage Drug Candidates (Phase I & Phase II) Consumption and Growth Rate (2017-2022)
-
Figure Global Late-stage Drug Candidates (Phase III & Registration Phase) Consumption and Growth Rate (2017-2022)
-
Figure Global Prostacyclin and Prostacyclin Analogs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Endothelin Receptor Antagonists Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Phosphodiesterase-5 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Soluble Guanylate Cyclase Stimulators Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Early-stage Drug Candidates (Phase I & Phase II) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Late-stage Drug Candidates (Phase III & Registration Phase) Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Pulmonary Hypertension Drug Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Pulmonary Hypertension Drug Export by Region (Top 5 Countries) (2017-2028)
-
Table AstraZeneca plc (Foundation Year, Company Profile and etc.)
-
Table AstraZeneca plc Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca plc Pulmonary Hypertension Drug Product and Service
-
Table Merck & Co, Inc (Foundation Year, Company Profile and etc.)
-
Table Merck & Co, Inc Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck & Co, Inc Pulmonary Hypertension Drug Product and Service
-
Table Pfizer Inc (Foundation Year, Company Profile and etc.)
-
Table Pfizer Inc Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Inc Pulmonary Hypertension Drug Product and Service
-
Table F Hoffmann-La Roche AG (Foundation Year, Company Profile and etc.)
-
Table F Hoffmann-La Roche AG Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffmann-La Roche AG Pulmonary Hypertension Drug Product and Service
-
Table Abbott Laboratories (Foundation Year, Company Profile and etc.)
-
Table Abbott Laboratories Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abbott Laboratories Pulmonary Hypertension Drug Product and Service
-
Table Novartis AG (Foundation Year, Company Profile and etc.)
-
Table Novartis AG Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis AG Pulmonary Hypertension Drug Product and Service
-
Table Boehringer Ingelheim GmbH (Foundation Year, Company Profile and etc.)
-
Table Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Product and Service
-
Table GlaxoSmithKline plc (Foundation Year, Company Profile and etc.)
-
Table GlaxoSmithKline plc Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline plc Pulmonary Hypertension Drug Product and Service
-
Table Vectura Group plc (Foundation Year, Company Profile and etc.)
-
Table Vectura Group plc Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Vectura Group plc Pulmonary Hypertension Drug Product and Service
-
Table Teva Pharmaceutical Industries Ltd (Foundation Year, Company Profile and etc.)
-
Table Teva Pharmaceutical Industries Ltd Pulmonary Hypertension Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical Industries Ltd Pulmonary Hypertension Drug Product and Service
-
